evodiamine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZS; Li, D; Qiu, Y; Wu, L; Xu, J; Xu, S; Yang, DH; Yao, H; Zhou, M | 1 |
1 other study(ies) available for evodiamine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds; Humans; Polycyclic Compounds; Quinazolines; Triple Negative Breast Neoplasms | 2021 |